News & Events about Lava Therapeutics Nv.
Globe Newswire
2 months ago
UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody platform of bispecific gamma-delta T cell engagers, today announced the appointment of Christy...
Globe Newswire
3 months ago
UTRECT, The Netherlands and PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq LVTX), an immuno-oncology company focused on developing its proprietary Gammabody platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that ...
Globe Newswire
4 months ago
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that...
Globe Newswire
5 months ago
Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA BoardUTRECHT, The Netherlands and PHILADELPHIA, Jan. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody platform of bispecific gamma ...
Globe Newswire
5 months ago
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today ...